期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (2)
Background The current study aims to empirically evaluate the direct relationship between the proportion of pharmaceutical spending and total medical ......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (2)
Objective The aim of the present study was to evaluate the cost-effectiveness ratio of surgical treatment options for small hepatocellular carcinoma (......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (5)
Objectives This study aims to systematically review the studies on the cost-effectiveness of stereotactic body radiotherapy (SBRT) in the treatment of......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (7)
Objective The purpose of this research was to create a function for mapping the cancer-specific instrument (FACT-G) to a preference-based measure (EQ-......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (4)
Objectives This study aims to update the statistics on the economic burden of T2DM and to identify the factors affecting the economic costs of T2DM in......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (7)
Background Donafenib and lenvatinib are approved by China National Medical Products Administration and recommended as first-line treatment of Metastat......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (1)
Objectives From the demand-side perspective, the monetary value of one additional quality-adjusted life year (QALY) is estimated as willingness-to-pay......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (4)
Objective To evaluate the cost-effectiveness of durvalumab in post-chemoradiotherapy patients with unresectable stage III NSCLC from the Chinese healt......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (7)
Plain Language Summary Metastatic HER-2 positive breast cancer poses a considerable cost to society due to limitations in health care resources. HLX02......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (8)
Background This study seeks to assess the quality of HEEs reporting on screening programs over the last 20 years in China, to identify potential predi......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (1)
Objectives: Durvalumab plus chemotherapy could significantly improve overall survival compared with chemotherapy alone in the first-line treatment of ......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (4)
Introduction Dipeptidyl peptidase-4 inhibitors (DPP-4i) are widely used oral antidiabetic agents that exert antihyperglycemic effects in type 2 diabet......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022; 22 (3)
Objective: We evaluated the cost-effectiveness of olaparib and niraparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, ; ()
Objectives: Durvalumab plus chemotherapy could significantly improve overall survival compared with chemotherapy alone in the first-line treatment of ......
期刊： EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, ; ()
Background: Hidradenitis suppurativa (HS) is a, chronic skin disease affecting up to 1% of the population in Europe. This study aims to assess the cos......
